HOME>About Canon>CSR Activities>For Society: Creating new value and solving social issues>Contributing to a Better Tomorrow for All

Contributing to a Better Tomorrow for All

The World of Next-Generation Healthcare Made Possible with Canon's Cutting-Edge Medical Imaging Technologies

Canon U.S. Life Sciences is developing reagents and genetic testing systems for researchCanon U.S. Life Sciences is developing reagents and genetic testing systems for research

Issues and Approach

Health Spending as a Share of GDP (OECD Average)

Health Spending as a Share of GDP (OECD Average)

  • Source: OECD Health Statistics 2015

Major technological innovations being achieved in medicine today are fulfilling people's desire to live a long, healthy life. In this pursuit, a large number of medical institutions and companies are advancing efforts in various fields, including the analysis of genetic information, the development of regenerative medicine, and the digitization of medical devices and medical information, to name but a few. Meanwhile, soaring health spending and insurance costs resulting from the aging of society and the onset of lifestyle diseases have become major social issues for many countries around the world. This has placed even greater expectations on preventive medicine as a means for early detection and early treatment.
Since developing an indirect X-ray camera effective in diagnosing tuberculosis during the epidemic in the 1940s, shortly after the company's founding, Canon has gone on to develop a number of medical devices utilizing its diagnostic imaging technologies, including retinal cameras and digital radiography equipment. Such devices have proved to be a great support to the frontlines of medicine, contributing to the early detection and early treatment of diseases.
Given the expected spread of precision medicine in which treatment and prevention methods are tailored to each individual patient, in the United States, a world leader in the healthcare industry, research and development is being advanced on genetic testing systems and reagent cartridges. In 2015, Canon BioMedical, Inc. was established as an integrated biomedical business covering R&D, production and marketing. As a world headquarters for the biomedical business, Canon BioMedical plans on expanding operations not only within the United States but also to Europe and other parts of the world.
Canon will in 2016 launch in Japan its Healthcare Information Platform, a new cloud-based solution that links medical-imaging data with patient information to facilitate the integrated management and sharing of medical image data. By making it easier for medical institutions to share and manage images, Canon seeks to assist people living in areas with few medical facilities to gain access to early detection and specialized treatment of illnesses.

Case Study

Identifying the Optimal Treatment Options for Each Individual Using Genetic Testing Technologies

Genetic diagnosis involvesidentifying the cause of an illness ordetermining the risk of developing an illness by analyzing genetic (DNA) information, the "blueprint" for life. In the United States, where genetic diagnosis is widely employed, test results from specialized testing centers are already being used to help determine approaches to take in treating diseases.
Canon U.S. Life Sciences, Inc. is developing a prototype genotyping platform and test reagent cartridges, utilizing Canon's CMOS sensor and inkjet printer technologies to quickly and accurately detect genetic mutations. Canon's DNA testing system is expected to shorten hands-on time from a whole day or more to only a few hours, and also to dramatically lower testing costs. Furthermore, it would also be possible to encourage from an early stage lifestyles that reduce the risk of onset of age-associated genetic disorders. For such reasons, these solutions are also stirring up anticipation from a preventive medicine standpoint. Canon U.S. Life Sciences is collaborating with universities and other research institutes, such as the University of Florida and the University of Utah, to conduct applied research on more precise devices and test reagents, with the aim of finalizing product specifications suitable for clinical use.

A prototype genotyping platform for research is currently under development
A prototype genotyping platform for research is currently under development

CSR Activities